Compare iShares Core S&P 500 ETF (IVV) vs Neurocrine Biosciences Inc (NBIX) Price & Performance

iShares Core S&P 500 ETFTrade

Neurocrine Biosciences IncTrade

Price performance (Past 24H)

Key statistics

iShares Core S&P 500 ETF vs Neurocrine Biosciences Inc — how do they compare? iShares Core S&P 500 ETF trades at $751.66, while Neurocrine Biosciences Inc trades at $179 (market cap $17.40B). Which is the better fit depends on your goals.

	IVV	NBIX
Sector	Broad Market / Factor	Health
52-Week High	$763.10	$180.55
52-Week Low	$624.65	$123.10
Market Cap	—	$17.40B
Enterprise Value	—	$16.49B

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

IVV

Invesco S&P 500 Equal Weight Consumer Discretionary ETF seen as a Hold, likely underperforming IVV again.Seeking Alpha · 2 days agoNeutral BlackRock's MAXJ ETF offers S&P 500 returns with downside protection but caps gains at 10.6%.24/7 Wall Street · 3 days agoNeutral SPY ETF charges higher fees than its cheaper sibling SPYM with identical S&P 500 exposure.24/7 Wall Street · 4 days agoBearish View details →

NBIX

Neurocrine Biosciences appoints Samir Siddhanti as Chief Business Officer to lead growth strategy.PRNewsWire · 7 hours agoBullish View details →

About iShares Core S&P 500 ETF

IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.